Ticker: KPTI

Karyopharm Therapeutics saw a 10% stock increase after Phase 3 trial data showed significant spleen volume reduction but no symptom improvement in myelofibrosis patients treated with selinexor plus ruxolitinib.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) - quick read on what's happening inside the company Bottom line: management is executing cost cuts and advancing Phase 3 programs while simultaneously running short on liquidity and facing heavy debt maturities and covenants. The company has announced B...